Capstan Medical Raises $110M for Heart Valve with Robotic System

Capstan Medical, a Santa Cruz-based medtech startup, has raised $110 million in an oversubscribed Series C funding round to advance its robotic-assisted heart valve implant platform. Backed by notable investors like Intuitive Ventures and Eclipse, the company is gearing up for first-in-human trials of its mitral valve technology in early 2025, with pivotal trials scheduled for 2026. This funding will also accelerate the development of Capstan’s tricuspid valve replacement implant, both of which will leverage the same cutting-edge robotic platform. By addressing mitral valve regurgitation and tricuspid valve disease—areas with significant unmet patient needs—Capstan aims to provide minimally invasive, next-generation cardiac solutions.

Taking on market leaders like Abbott and Edwards Lifesciences, Capstan’s innovative robotic platform sets it apart as the first of its kind in this space. Unlike existing treatments, such as Abbott’s MitraClip and Edwards’ Pascal systems, Capstan’s approach integrates robotics to enhance precision, reduce invasiveness, and improve patient outcomes. With its technology potentially expanding to aortic valve treatment in the future, Capstan is positioning itself as a formidable competitor in the rapidly growing cardiac device market.